Page 6 - Piramal Enterprises

India's widening debt market cracks threaten to swallow realty tycoons

The weak performance of property businesses and an acute liquidity crunch were cited as key reasons for rating downgrades

High-leverage entities losing favour amid worries of corporate defaults

Investors looking to shift funds to firms with comfortable debt levels

Piramal sells entire stake in Shriram Transport for around Rs 2,300 crore

Market sources said the company sold its shares for around Rs 1,000-1,015 a share

Outlook for Piramal Enterprises is not bright; stock falls over 3%

Further unwinding of positions in Shriram Group firms is key worry

House is a good investment if one has a three-year horizon: Anand Piramal

Piramal says the company would look at a CAGR of 20 per cent over the next decade, despite the subdued property markets

Piramal Enterprises' partner launches kidney ailment drug in US markets

This is the first major launch by Piramal Pharma Solutions through a partner

Piramal Enterprises cuts exposure to realtors, raises home finance share

Piramal Capital & Housing Finance had a loan book of Rs 55,255 crore as on end-December

Piramal and CDPQ of Canada to invest Rs 500 cr in Lodha's Palava smart city

The equity investment in Palava, in Mumbai Metropolitan region, is being done from the Piramal Ivanhoe Residential Equity Fund

Piramal Enterprises to reduce its exposure to realty developers

Housing finance loans to constitute 10% of the loan book by March 2019

Piramal Enterprises to allot 25000 NCDs aggregating Rs 25 billion

These NCDs are proposed to be listed on wholesale debt market segment of NSE, Piramal Enterprises said in a BSE filing

Piramal Enterprises refutes rumour of realty firms' default to lending arm

Piramal Enterprises (PEL) Sunday said it "strongly refutes baseless rumours" regarding loan defaults by real estate developers to its lending arms Piramal Capital & Housing Finance Ltd. Further, the company said it "would categorically like to state that we have an extremely robust loan processing and recovery process including risk management and asset monitoring system." Developers like Lodha, Omkar, Vatika and Embassy referred to in the rumours are part of the lending portfolio but have never defaulted on any interest or repayment obligation to PEL/PCHFL, it said said. "Among others the rumours relate to loan defaults to PEL/Piramal Capital & Housing Finance Limited (PCHFL) by real estate developers such as Lodha, Omkar, Vatika, Embassy, Radius, Nahar, Aristo, Supertech etc," it said in a statement. PEL said it "strongly refutes all baseless rumours" of any sort/form that have been floating around with respect to its real estate loan portfolio companies. Additionally, ...

Piramal Enterprises denies loan defaults by Lodha, Omkar, Vatika and others

The speculation was perhaps linked to the National Housing Board (NHB) starting its annual inspection of PCHFL

Piramal Enterprises Q3 consolidated net rises 21% to Rs 4.9 billion

Pharma segment revenues grew by 7% to Rs 10.22 bn

Piramal Enterprises Q3 net profit up 21% at Rs 4.90 billion

The company had posted a net profit of Rs 4.04 billion in the year-ago period

Piramal Enterprises plans Rs 7k cr fundraising via debentures, rights issue

Company plans to raise Rs 2,000 cr through a rights issue with an issue price of Rs 2,380 per equity share

Piramal invests $55 million to upgrade API plants

In a boost to its contract manufacturing business, Piramal Enterprises has invested $ 55 million (around Rs 360 crore ) to upgrade its active pharmaceutical ingredient manufacturing plants in India and the US.Healthcare is the largest segment of the company and contributed to around 47 per cent of the company's FY 17 revenue of Rs 8547 crore. Within healthcare, contract manufacturing is the largest division accounting for 60 per cent of the segment revenue in last fiscal.The contract manufacturing business supports clinical trials and drug development of other companies. It has five manufacturing sites in India, the US and Europe.A part of the investment will go into a new state of art multi purpose plants to support the current pipeline of around 80 late stage programmes that the company is currently assisting its partners. The investment has been made through group company Piramal Pharma Solutions.Upgrades will include creation of early development capabilities, addition of GMP ...

Piramal Enterprises to raise Rs 600-cr via NCDs

The company's stock closed at Rs 2,881.85, down 0.97%, on BSE

Piramal Enterprises Q1 net profit up 43% to Rs 247.46 crore

The firm had posted a net profit of Rs 172.93 crore during the April-June quarter of FY17

Piramal Enterprises' bets on Shriram group pay off

Gains Rs 2,787 crore on investments in two listed entities of the group

Piramal Enterprises to raise up to Rs 125 cr via non-convertible debentures

Shares of Piramal Enterprises closed 0.19% lower at Rs 2,908.40 per scrip on BSE